Dal-OUTCOMES (Afgerond)
A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients.
- Middel
- cetp-remmer
- Populatie
- ASCVD
- Fase
- III
- Jaar aanvang
- 2008
- Meer informatie
- ClinicalTrials.gov